Table 1 Baseline characteristics
All patients n = 37 | EGPAa n = 22 | GPAa n = 15 | |
|---|---|---|---|
Age (yrs) | 55 ± 16 | 54 ± 16 | 55 ± 16 |
Gender (male) | 13 (35%) | 5 (23%) | 8 (53%) |
Cardiovascular risk factors | |||
Diabetes | 7 (19%) | 5 (23%) | 2 (13%) |
Hypertension | 13 (35%) | 8 (36%) | 5 (33%) |
Smokingb | 13 (35%) | 7 (32%) | 6 (40%) |
Hyperlipidemia | 6 (16%) | 5 (23%) | 1 (7%) |
Family history of CVD | 11 (30%) | 8 (36%) | 3 (20%) |
Obesity (BMI ≥ 30 kg/m2) | 9 (24%) | 5 (23%) | 4 (27%) |
Symptoms (multiple possible) | |||
Angina | 6 (16%) | 4 (18%) | 2 (13%) |
Dyspnea | 16 (43%) | 12 (54%) | 4 (27%) |
Palpitations | 4 (11%) | 4 (18%) | - |
Syncope | 1 (3%) | 1 (5%) | - |
ECG abnormality | 11 (30%) | 9 (41%) | 2 (13%) |
Years since diagnosis | |||
3 (0–11) | 4 (0–11) | 2 (0–11) | |
< 1 | 12 (32%) | 6 (27%) | 6 (40%) |
1–4 | 11 (30%) | 5 (23%) | 6 (40%) |
5–9 | 11 (30%) | 10 (46%) | 1 (7%) |
≥ 10 | 3 (8%) | 1 (5%) | 2 (13%) |
Disease Activity | |||
BVAS | 5.5 (1–14) | 5 (3–8) | 11.5 (0–24) |
Hematocrit | 0.39 (0.36–0.42) | 0.4 (0.38–0.42) | 0.38 (0.32–0.42) |
Medication | |||
Beta-blockers | 9 (24%) | 6 (27%) | 3 (20%) |
ARB | 14 (38%) | 7 (32%) | 7 (47%) |
ASA | 5 (14%) | 5 (23%) | - |
CCB | 8 (22%) | 4 (18%) | 4 (27%) |
Statins | 3 (8%) | 2 (9%) | 1 (7%) |
Diuretics | 8 (22%) | 7 (32%) | 1 (7%) |
Steroids | 37 (100%) | 22 (100%) | 15 (100%) |
NSAID | 1 (3%) | 1 (5%) | - |
Antibodies | 2 (5%) | 1 (5%) | 1 (7%) |
Cyclophosphamide | 17 (46%) | 4 (18%) | 13 (87%) |
Azathioprine | 4 (11%) | 2 (9%) | 2 (13%) |
Methotrexate | 5 (14%) | 4 (18%) | 1 (7%) |